Hidradenitis suppurativa Sweat Gland Diseases
Conditions
Interventions
This is a prospective, observational, and non-randomized single-arm cohort study that evaluated the clinical effect of photobiomodulation (660 nanometers, 100 milliwatts, 1 Joule per square centimeter
the experimental group included 15 participants (men and women) diagnosed by a clinical dermatologist, totaling 48 wounds
as it is a single-arm study, there was no control group or randomization process (randomization of participants)
the treatment was performed once a week for four weeks, with direct light application for 30 seconds on each lesion
the evaluation included the Hidradenitis Suppurativa Clinical Response (HiSCR) tool for lesion counting, the Dermatology Life Quality Index (DLQI-BRA) questionnaire, and pain assessment through the qu
if the answer was positive, a pain scale was used to measure its intensity
reports of burning, stinging, discomfort, and irritation in the area were also classified as pain
at the first moment (Time 0) and at the last meeting (Time 4), the affected area was photographed with the same device and at the same distance for complementary evaluation of the superficial inflamma
the images were anonymized and coded to ensure participant confidentiality
the analysis focused on visual signs of inflammation (erythema, edema, and exudate), superficial characteristics, and nodule diameter
this evaluation was conducted by two trained and independent specialists (a nurse and a physician), in a blind masking system (the evaluators did not know at which stage of treatment the photo was tak
in case of divergence, a third specialist nurse was consulted
Sponsors
Hospital de Clínicas da Universidade Estadual de Campinas
Hospital de Clínicas da Universidade Estadual de Campinas
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Participants diagnosed with hidradenitis suppurativa who present with active lesions; individuals over eighteen years of age; patients capable of participating in the study autonomously and without cognitive impairment.
Exclusion criteria
Exclusion criteria: Participants with skin lesions or inflammatory conditions that have not yet been formally diagnosed as hidradenitis suppurativa by a medical professional; individuals who missed more than two consecutive treatment sessions during the four-week intervention period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected Outcome 1: Reduction in the number of abscesses and inflammatory nodules;Outcome Found1: A reduction in the number of abscesses and inflammatory nodules was found in participants with hidradenitis suppurativa, verified by direct counting of lesions ;Expected Outcome 2: Reduction in visual signs of inflammation;Outcome found 2: A decrease in visual signs of inflammation (pathological process of tissue injury) was found, specifically a reduction in erythema, edema, and the presence of exudate, assessed through clinical visual inspection and comparative analysis of standardized photographs | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 3: Improvement in participants' quality of life, assessed by the change in total score on the Dermatology Life Quality Index (DLQI - Brazilian version) questionnaire;Outcome found 3: An improvement in quality of life was observed, verified by the reduction/variation in the DLQI score between the initial moment and after the completion of the interventions;Expected outcome 4: Reduction in pain intensity and sensory symptoms (burning, stinging, and discomfort) in the affected area;Outcome 4: A reduction in pain intensity, as measured by the Numerical Pain Scale (0-10), and a decrease in sensory symptoms reported by participants were observed | — |
Countries
BR
Contacts
Public ContactThays Freitas
Universidade Estadual de Campinas
Outcome results
None listed